Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long. Small clinical trials have previously shown that TKI-therapy can be stopped in 40-60% of patients with a very good therapy response.

The purpose in EURO-SKI was to determine the proportion of patients keeping their therapy response after stopping TKIs and to determine clinical and biological factors that predict successful TKI-stop.

868 patients at 61 sites in 11 European countries were registered in study. Patients were required to have had at least three years of TKI-therapy and to have had a very good response (MR4) to therapy for at least one year prior to study entry. Only patients who had not failed prior TKI-treatment were included.

Results of the trial show that 62% of the patients still maintained treatment response (MMR) 6 months after stopping therapy. This was 56% at 12 months. Duration of TKI therapy and of very good therapy response (MR4) prior to stop was found to predict successful stop. However, neither gender, age or risk score of the disease were linked to likelihood of successful stopping of TKI therapy.

Presenter: Dr Johan Richter

Affiliation: Lund, Sweden, Francois-Xavier Mahon, Bordeaux, France and Susanne Saussele, Mannheim, Germany.

Topic: STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL

Abstract S145 will be presented by Johan Richter on Friday, June 10, 2016, 15:45 - 15:55 in Hall A1.

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.

Contact

EHA Executive Office

Ineke van der Beek, Jon Tarifa

E-mail: communication@ehaweb.org

Mobile: +31(0)6 2011 1055

 

Last Updated on Tuesday 05 June 2018.